HCW Biologics remains in a high-risk, pre-commercial development phase characterized by extreme revenue volatility and a persistent reliance on external financing.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 14, 2026 | -$11.58-484.8% vs -$1.98 | $135,568+0.0% vs $135,568 |
Q2 2026 May 14, 2026 | $2.22+184.1% vs -$2.64 | $7M-0.2% vs $7M |
Q2 2026 Mar 31, 2026 | -$15.78-213.1% vs -$5.04 | $27,010-99.6% vs $7M |
Q4 2025 Nov 14, 2025 | -$12.12-227.8% vs $9.48 | $85,285-98.8% vs $7M |
HCW Biologics Inc. (NASDAQ: HCWB - Get Free Report) was the target of a large increase in short interest during the month of September. As of September 30th, there was short interest totaling 60,941 shares, an increase of 557.1% from the September 15th total of 9,274 shares. Based on an average daily trading volume, of 1,348,961
Communication with FDA at recent Type B meeting provided clear guidance for next steps to prepare IND application to support first-in-human clinical study in cancer
MIRAMAR, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today announced the pricing of its $1.5 million private placement (the “Offering”) with an existing stockholder of the Company, (the “Investor”).
Agreement includes pre-payment commitments for product sales and distribution of the second-generation multi-cytokine-based HCW11-006 for use as a reagent
Benchmark HCWB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for HCW Biologics Inc. (HCWB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.02 | $354.59K | -0.07 | -97.89% | -73.22% | -142.16% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $25.55 | $3.2B | 116.88 | 91.34% | 5.88% | 14.18% | — | |
| $131.73 | $10.84B | -37.73 | -16.72% | -341.87% | -22.39% | — | |
| $18.28 | $2.3B | -5.23 | -4.26% | -445% | -90.04% | — | |
| $59.83 | $9.16B | 21.31 | 87.32% | 55.22% | 72.3% | — |
HCW Biologics Inc. (HCWB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
HCW Biologics Inc. (HCWB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 14, 2026·SEC
Aug 14, 2026·SEC
Jul 29, 2026·SEC
Mar 31, 2026·SEC
Get notified when HCWB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HCW Biologics Inc. (HCWB) stock FAQ — growth, dividends, profitability & financials explained
HCW Biologics Inc. (HCWB) reported $6.7M in revenue over the trailing twelve months. Revenue was $0.1M in fiscal year 2025.
HCW Biologics Inc. (HCWB) grew revenue by 707.0% over the trailing twelve months, compared with the twelve months before.
No. HCW Biologics Inc. (HCWB) reported a net loss of $4.9M over the trailing twelve months.
HCW Biologics Inc. (HCWB) had a return on equity (ROE) of -142.2% over the trailing twelve months. A negative ROE means the company lost money over the period.
HCW Biologics Inc. (HCWB) had negative free cash flow of $12.1M over the trailing twelve months.
